These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33922992)

  • 1. Induction of Apoptosis, Inhibition of MCL-1, and VEGF-A Expression Are Associated with the Anti-Cancer Efficacy of Magnolol Combined with Regorafenib in Hepatocellular Carcinoma.
    Chen CH; Hsu FT; Chen WL; Chen JH
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models.
    Cucarull B; Tutusaus A; Subías M; Stefanovic M; Hernáez-Alsina T; Boix L; Reig M; García de Frutos P; Marí M; Colell A; Bruix J; Morales A
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32024199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.
    Xu J; Huang F; Yao Z; Jia C; Xiong Z; Liang H; Lin N; Deng M
    Cell Commun Signal; 2019 Jul; 17(1):85. PubMed ID: 31349793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo.
    Chen JH; Chiang IT; Hsu FT
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31905887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
    Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
    BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis induction and ERK/NF-κB inactivation are associated with magnolol-inhibited tumor progression in hepatocellular carcinoma in vivo.
    Tsai JJ; Chen JH; Chen CH; Chung JG; Hsu FT
    Environ Toxicol; 2020 Feb; 35(2):167-175. PubMed ID: 31714653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with regorafenib in the treatment of hepatocellular carcinoma.
    Granito A; Forgione A; Marinelli S; Renzulli M; Ielasi L; Sansone V; Benevento F; Piscaglia F; Tovoli F
    Therap Adv Gastroenterol; 2021; 14():17562848211016959. PubMed ID: 34104211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo.
    Pan PJ; Liu YC; Hsu FT
    J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31238539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma.
    Shi W; Zhang S; Ma D; Yan D; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
    Front Oncol; 2020; 10():694. PubMed ID: 32670862
    [No Abstract]   [Full Text] [Related]  

  • 11. Magnolol Induces Apoptosis and Inhibits ERK-modulated Metastatic Potential in Hepatocellular Carcinoma Cells.
    Kuan LY; Chen WL; Chen JH; Hsu FT; Liu TT; Chen WT; Wang KL; Chen WC; Liu YC; Wang WS
    In Vivo; 2018; 32(6):1361-1368. PubMed ID: 30348689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Berberine Sensitizes Human Hepatoma Cells to Regorafenib via Modulating Expression of Circular RNAs.
    Wang K; Yu G; Lin J; Wang Z; Lu Q; Gu C; Yang T; Liu S; Yang H
    Front Pharmacol; 2021; 12():632201. PubMed ID: 34220494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
    Yu CC; Huang SY; Chang SF; Liao KF; Chiu SC
    Molecules; 2020 May; 25(10):. PubMed ID: 32466169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving regorafenib's organ target precision via nano-assembly to change its delivery mode abolishes chemoresistance and liver metastasis of colorectal cancer.
    Liu J; Fu D; Wang K; Yuan Y; Deng Y; Shi L; Li M; Zhou C; Lu X; Lv Q; Wang G; Wang L; Wang Z
    J Colloid Interface Sci; 2022 Feb; 607(Pt 1):229-241. PubMed ID: 34500422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial dysfunction.
    Wang R; Liu Y; Mi X; Chen Q; Jiang P; Hou J; Lin Y; Li S; Ji B; Fang Y
    Arch Biochem Biophys; 2020 Aug; 689():108415. PubMed ID: 32562663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo.
    Weng MC; Li MH; Chung JG; Liu YC; Wu JY; Hsu FT; Wang HE
    Biomed Pharmacother; 2019 Aug; 116():109032. PubMed ID: 31163381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
    Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
    Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells.
    Refolo MG; Lippolis C; Carella N; Cavallini A; Messa C; D'Alessandro R
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines.
    Digiacomo G; Fumarola C; La Monica S; Bonelli MA; Cretella D; Alfieri R; Cavazzoni A; Galetti M; Bertolini P; Missale G; Petronini PG
    Front Oncol; 2020; 10():563249. PubMed ID: 33072590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.